MovDisordV3, Main, Exploration, bibRecord, 004114

Double‐blind, single‐dose, cross‐over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease

Identifieur interne : 004114 ( Main/Exploration ); précédent : 004113; suivant : 004115

Double‐blind, single‐dose, cross‐over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease

Auteurs : Prithiva Navan [Royaume-Uni] ; Leslie J. Findley [Royaume-Uni] ; Jim A. R. Jeffs [Royaume-Uni] ; Ronald K. B. Pearce [Royaume-Uni] ; Peter G. Bain [Royaume-Uni]

Source :

Movement Disorders [ 0885-3185 ] ; 2003-02.

RBID : ISTEX:8B91460D58799BBD94564EE9A15CE417C4BF507A

Descripteurs français

Pascal (Inist)
- Agoniste, Antiparkinsonien, Chimiothérapie, Ergot dérivé, Etude double insu, Homme, Parkinson maladie, Pergolide, Pramipexole, Récepteur dopaminergique D2, Traitement, Tremblement repos.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Aged, Aged, 80 and over, Agonist, Analysis of Variance, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Benzothiazoles, Chemotherapy, Cross-Over Studies, D2 Dopamine receptor, Dopamine Agonists (administration & dosage), Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Dose-Response Relationship, Drug, Double blind study, Double-Blind Method, Ergot derivatives, Female, Human, Humans, Male, Middle Aged, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Pergolide, Pergolide (administration & dosage), Pergolide (adverse effects), Pergolide (therapeutic use), Pramipexole, Questionnaires, Resting tremor, Thiazoles (administration & dosage), Thiazoles (adverse effects), Thiazoles (therapeutic use), Treatment, Tremor (diagnosis), Tremor (drug therapy), Tremor (etiology), pergolide, pramipexole, tremor.
MESH :
- chemical , administration & dosage : Antiparkinson Agents, Dopamine Agonists, Pergolide, Thiazoles.
- chemical , adverse effects : Antiparkinson Agents, Dopamine Agonists, Pergolide, Thiazoles.
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agonists, Pergolide, Thiazoles.
- complications : Parkinson Disease.
- diagnosis : Tremor.
- drug therapy : Parkinson Disease, Tremor.
- etiology : Tremor.
- Aged, Aged, 80 and over, Analysis of Variance, Benzothiazoles, Cross-Over Studies, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Questionnaires.

Abstract

Tremor is one of the cardinal signs of Parkinson's disease (PD) but its response to antiparkinsonian medication is variable. It has been postulated that pramipexole may have a stronger antiparkinsonian tremor effect than pergolide, another direct acting dopamine agonist medication, possibly because the former has preferential affinity for the dopamine D3 receptor. The purpose of this pilot study was to compare the effects of a single oral dose of either pramipexole (Pr) or pergolide (Pe) or placebo (Pl) on parkinsonian tremor and the motor (part III) subsection of the UPDRS. Ten patients (6 men, 4 women), mean age 65.3 years, mean duration from diagnosis of 2.6 years, with tremor dominant PD were recruited. On three separate occasions a single dose of pramipexole (salt) 500 μg, pergolide 500 μg or placebo were administered in random order to each patient, who were pretreated with domperidone and had their antiparkinsonian medication withheld from midnight before study. After each medication patients were assessed at baseline and then every 30 min for 4 hr using a 0 to 10 tremor rating scale and the UPDRS (part III) in a double‐blind protocol. Adverse effects were systematically recorded. The results demonstrate that 500 μg of either pramipexole or pergolide reduced PD rest tremor scores to a similar degree, which at peak effect was significantly greater than placebo (respectively Pe v Pl: P < 0.006, Pr v Pl: P < 0.033). The two active drugs also had weaker beneficial effects on the UPDRS part III. Pergolide, however, was significantly more likely than pramipexole to cause nausea (P = 0.005) or vomiting (P = 0.014). © 2002 Movement Disorder Society

Url:

https://api.istex.fr/document/8B91460D58799BBD94564EE9A15CE417C4BF507A/fulltext/pdf

DOI: 10.1002/mds.10320

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Double‐blind, single‐dose, cross‐over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease</title>
<author><name sortKey="Navan, Prithiva" sort="Navan, Prithiva" uniqKey="Navan P" first="Prithiva" last="Navan">Prithiva Navan</name>
</author>
<author><name sortKey="Findley, Leslie J" sort="Findley, Leslie J" uniqKey="Findley L" first="Leslie J." last="Findley">Leslie J. Findley</name>
</author>
<author><name sortKey="Jeffs, Jim A R" sort="Jeffs, Jim A R" uniqKey="Jeffs J" first="Jim A. R." last="Jeffs">Jim A. R. Jeffs</name>
</author>
<author><name sortKey="Pearce, Ronald K B" sort="Pearce, Ronald K B" uniqKey="Pearce R" first="Ronald K. B." last="Pearce">Ronald K. B. Pearce</name>
</author>
<author><name sortKey="Bain, Peter G" sort="Bain, Peter G" uniqKey="Bain P" first="Peter G." last="Bain">Peter G. Bain</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:8B91460D58799BBD94564EE9A15CE417C4BF507A</idno>
<date when="2003" year="2003">2003</date>
<idno type="doi">10.1002/mds.10320</idno>
<idno type="url">https://api.istex.fr/document/8B91460D58799BBD94564EE9A15CE417C4BF507A/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001B22</idno>
<idno type="wicri:Area/Istex/Curation">001B22</idno>
<idno type="wicri:Area/Istex/Checkpoint">002A44</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Navan P:double:blind:single</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12539211</idno>
<idno type="wicri:Area/PubMed/Corpus">003853</idno>
<idno type="wicri:Area/PubMed/Curation">003853</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003801</idno>
<idno type="wicri:Area/Ncbi/Merge">000998</idno>
<idno type="wicri:Area/Ncbi/Curation">000998</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000998</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Navan P:double:blind:single</idno>
<idno type="wicri:Area/Main/Merge">005D37</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:03-0171577</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002540</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000781</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002477</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Navan P:double:blind:single</idno>
<idno type="wicri:Area/Main/Merge">006023</idno>
<idno type="wicri:Area/Main/Curation">004114</idno>
<idno type="wicri:Area/Main/Exploration">004114</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Double‐blind, single‐dose, cross‐over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease</title>
<author><name sortKey="Navan, Prithiva" sort="Navan, Prithiva" uniqKey="Navan P" first="Prithiva" last="Navan">Prithiva Navan</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Division of Neurosciences and Psychological Medicine, Imperial College School of Medicine, Charing Cross Hospital Campus, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Findley, Leslie J" sort="Findley, Leslie J" uniqKey="Findley L" first="Leslie J." last="Findley">Leslie J. Findley</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Essex Centre for Neurological Sciences, Havering Hospital NHS Trust, Essex</wicri:regionArea>
<wicri:noRegion>Essex</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jeffs, Jim A R" sort="Jeffs, Jim A R" uniqKey="Jeffs J" first="Jim A. R." last="Jeffs">Jim A. R. Jeffs</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>The Statistical Consultancy Service, Department of Epidemiology and Public Health, Imperial College, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pearce, Ronald K B" sort="Pearce, Ronald K B" uniqKey="Pearce R" first="Ronald K. B." last="Pearce">Ronald K. B. Pearce</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Division of Neurosciences and Psychological Medicine, Imperial College School of Medicine, Charing Cross Hospital Campus, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bain, Peter G" sort="Bain, Peter G" uniqKey="Bain P" first="Peter G." last="Bain">Peter G. Bain</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Division of Neurosciences and Psychological Medicine, Imperial College School of Medicine, Charing Cross Hospital Campus, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2003-02">2003-02</date>
<biblScope unit="vol">18</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="176">176</biblScope>
<biblScope unit="page" to="180">180</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">8B91460D58799BBD94564EE9A15CE417C4BF507A</idno>
<idno type="DOI">10.1002/mds.10320</idno>
<idno type="ArticleID">MDS10320</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Agonist</term>
<term>Analysis of Variance</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Antiparkinson agent</term>
<term>Benzothiazoles</term>
<term>Chemotherapy</term>
<term>Cross-Over Studies</term>
<term>D2 Dopamine receptor</term>
<term>Dopamine Agonists (administration & dosage)</term>
<term>Dopamine Agonists (adverse effects)</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double blind study</term>
<term>Double-Blind Method</term>
<term>Ergot derivatives</term>
<term>Female</term>
<term>Human</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Pergolide</term>
<term>Pergolide (administration & dosage)</term>
<term>Pergolide (adverse effects)</term>
<term>Pergolide (therapeutic use)</term>
<term>Pramipexole</term>
<term>Questionnaires</term>
<term>Resting tremor</term>
<term>Thiazoles (administration & dosage)</term>
<term>Thiazoles (adverse effects)</term>
<term>Thiazoles (therapeutic use)</term>
<term>Treatment</term>
<term>Tremor (diagnosis)</term>
<term>Tremor (drug therapy)</term>
<term>Tremor (etiology)</term>
<term>pergolide</term>
<term>pramipexole</term>
<term>tremor</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agonists</term>
<term>Pergolide</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agonists</term>
<term>Pergolide</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agonists</term>
<term>Pergolide</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Tremor</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
<term>Tremor</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Tremor</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Analysis of Variance</term>
<term>Benzothiazoles</term>
<term>Cross-Over Studies</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Questionnaires</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Agoniste</term>
<term>Antiparkinsonien</term>
<term>Chimiothérapie</term>
<term>Ergot dérivé</term>
<term>Etude double insu</term>
<term>Homme</term>
<term>Parkinson maladie</term>
<term>Pergolide</term>
<term>Pramipexole</term>
<term>Récepteur dopaminergique D2</term>
<term>Traitement</term>
<term>Tremblement repos</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Tremor is one of the cardinal signs of Parkinson's disease (PD) but its response to antiparkinsonian medication is variable. It has been postulated that pramipexole may have a stronger antiparkinsonian tremor effect than pergolide, another direct acting dopamine agonist medication, possibly because the former has preferential affinity for the dopamine D3 receptor. The purpose of this pilot study was to compare the effects of a single oral dose of either pramipexole (Pr) or pergolide (Pe) or placebo (Pl) on parkinsonian tremor and the motor (part III) subsection of the UPDRS. Ten patients (6 men, 4 women), mean age 65.3 years, mean duration from diagnosis of 2.6 years, with tremor dominant PD were recruited. On three separate occasions a single dose of pramipexole (salt) 500 μg, pergolide 500 μg or placebo were administered in random order to each patient, who were pretreated with domperidone and had their antiparkinsonian medication withheld from midnight before study. After each medication patients were assessed at baseline and then every 30 min for 4 hr using a 0 to 10 tremor rating scale and the UPDRS (part III) in a double‐blind protocol. Adverse effects were systematically recorded. The results demonstrate that 500 μg of either pramipexole or pergolide reduced PD rest tremor scores to a similar degree, which at peak effect was significantly greater than placebo (respectively Pe v Pl: P < 0.006, Pr v Pl: P < 0.033). The two active drugs also had weaker beneficial effects on the UPDRS part III. Pergolide, however, was significantly more likely than pramipexole to cause nausea (P = 0.005) or vomiting (P = 0.014). © 2002 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
</region>
<settlement><li>Londres</li>
</settlement>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Navan, Prithiva" sort="Navan, Prithiva" uniqKey="Navan P" first="Prithiva" last="Navan">Prithiva Navan</name>
</region>
<name sortKey="Bain, Peter G" sort="Bain, Peter G" uniqKey="Bain P" first="Peter G." last="Bain">Peter G. Bain</name>
<name sortKey="Findley, Leslie J" sort="Findley, Leslie J" uniqKey="Findley L" first="Leslie J." last="Findley">Leslie J. Findley</name>
<name sortKey="Jeffs, Jim A R" sort="Jeffs, Jim A R" uniqKey="Jeffs J" first="Jim A. R." last="Jeffs">Jim A. R. Jeffs</name>
<name sortKey="Pearce, Ronald K B" sort="Pearce, Ronald K B" uniqKey="Pearce R" first="Ronald K. B." last="Pearce">Ronald K. B. Pearce</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004114 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004114 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:8B91460D58799BBD94564EE9A15CE417C4BF507A
   |texte=   Double‐blind, single‐dose, cross‐over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Double‐blind, single‐dose, cross‐over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease

Double‐blind, single‐dose, cross‐over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.